Top

World Journal of Urology

Published in:

01-10-2008 | Original Article

Serotonin used as prognostic marker of urological tumors

Authors: Nina Jungwirth, Lothar Haeberle, Karl Michael Schrott, Bernd Wullich, Frens Steffen Krause

Published in: World Journal of Urology | Issue 5/2008

Abstract

Introduction

In regard to therapy and prognosis of urological tumors, specific tumor markers are lacking especially in renal and urinary bladder carcinoma. Our study examines the relevance of serum serotonin levels to urinary bladder, prostate, renal, and testicular carcinoma when it comes to prognosis and occurrence of these oncological conditions.

Materials and methods

Serotonin levels were obtained in 109 patients presenting with urothelial carcinoma to the urinary bladder, adenocarcinoma of the prostate and renal cell carcinoma, as well as presenting with seminomatous and non-seminomatous testicular tumors. All of these conditions varied in grades and metastases. Serum levels were drawn between 7 and 8 a.m. exclusively in order to avoid circadian changes.

Results

Serotonin levels in urothelial carcinoma appeared within pathological range in correlation with tumor stage, life expectancy, and statistical significant with distant metastases. In prostate carcinoma, serotonin levels showed a tendency with organ exceeding growth, Grading/Gleason Score, PSA values >100 ng/ml, and the presence of distant metastases. In renal cell carcinoma, serotonin levels were decreased in patients with lymph node and distant metastases; there was no significant correlation with extent of infiltration. In regard to testicular carcinoma, decreased serotonin levels were merely noted in mixed tumors and the one extragonadal seminoma. Otherwise there was no correlation observed with stage and grade as well as with common tumor markers (AFP/βHCG).

Conclusion

Serotonin levels are suitable for prognostic evaluation of urothelial carcinoma in the urinary bladder, adenocarcinoma of the prostate, and renal cell carcinoma, especially taking into account the lab cost of 25€ per test.

Schubert- Fritschle G (2005) Nachsorge oder keine Nachsorge-das ist hier die Frage. Der Urologe 44(9):991–996PubMedCrossRef

Boonpipattanaponq T, Chewatanakornkul S (2006) Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol 40(7):592–595CrossRef

Stapel A, Franke U, Putzki H (1992) Significance of CEA and CA 19-9 for after care of curatively resected colorectal cancers. Zentralbl Chir 117(2):77–80PubMed

Bertz J, Giersiepen K, Haberland J, et al (2006) Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Robert Koch Institut

Kufer R, Hautmann R (2006) Dem Nierenzellkarzinom molekularbiologisch auf den Grund gegangen. Der Urologe 45(3):295–296PubMedCrossRef

Pottsek T (2005) Nachsorge beim Hodentumor lohnt sich. Der Urologe 44(9):1024–1030CrossRef

Winter E (2005) Diagnostik des Hodentumors. Dtsch Ärztebl 102(44A):3021–3025

Erspamer V, Vialli M (1951) Presence of enteramine in the skin of Amphibia. Nature 167:1033PubMedCrossRef

Twarog BM, Page IH (1953) Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 175(1):157–161PubMed

10.

Siddiqui EJ, Shabbir M, Mikhailidis DP et al (2006) The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation. BJU Int 97(3):634–639PubMedCrossRef

11.

Cunningham JL, Grimelius L, Sundin A et al (2007) Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with poorer prognosis. Acta Oncol 46(6):747–756PubMedCrossRef

12.

Siddiqui EJ, Thompson CS, Mikhailidis DP et al (2005) The role of serotonin in tumor growth. Oncol Rep 14(6):1593–1597PubMed

13.

Pyroja S, Joseph B, Paulose CS (2007) Increased 5-HT2C receptor binding in the brain stem and cerebral cortex during liver regeneration and hepatic neoplasia in rats. J Neurol Sci 254:3–8PubMedCrossRef

14.

Hauso O, Gustafsson BI, Loennechen JP et al (2007) Long-term effects in the rat are prevented by terguride. Regul Pept 143:39–46PubMedCrossRef

15.

Shuttleworth R, O’Brien J (1981) Intraplatelet serotonin and plasma 5-hydroxindoles in health and disease. Blood 57(3):505–509PubMed

16.

Pawlak D, Malczy E, Darewicz J et al (2000) Platelet serotonergic mechanisms in patients with cancer of the urinary bladder. Thromb Res 98:367–374PubMedCrossRef

17.

Bostwick DG, Qian J, Pacelli A et al (2002) Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 168(3):1204–1211PubMedCrossRef

18.

Dah-Shyong Y, Dar-Shih H, Hong-I C et al (2001) The expression of neuropeptides in hyperplastic and malignant prostate tissue and ist possible clinical implications. J Urol 166:871–875CrossRef

19.

Dizeyi N, Bjartell A, Nilsson E et al (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 59(3):328–336PubMedCrossRef

20.

de Herder WW (2007) Biochemistry of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 21(1):33–41PubMedCrossRef

21.

Pinski J, Wang Q, Quek ML et al (2006) Genistein-induced neuroendocrine differentiation of prostate cancer cells. Prostate 66(11):1136–1143PubMedCrossRef

22.

Sommerfeld H, Partin A, Pannek J (2002) Incidence of neuroendocrine cells in the seminal vesicles and the prostate—an immunohistochemical study. Int J Urol Nephrol 34:357–360CrossRef

23.

Siddiqui EJ, Shabbir M, Mikhailidis DP et al (2006) The role of serotonin receptors in prostate cancer cell proliferation. J Urol 176:1648–1653PubMedCrossRef

24.

Autorino R, Lamendola MG, De Luca G et al (2007) Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 Patients with prostate cancer. Int J Immunopathol Pharmacol 20(4):765–770PubMed

25.

Gunia S, Albrecht K, Koch S, et al (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-oberserver variability. World J Urol (online version, in print)

26.

Kamiya N, Suzuki H, Kawamura K et al (2008) Neuroendocrine differentiation in stage D2 prostate cancer. Int J Urol 15(5):423–428PubMedCrossRef

27.

Capdevila J, Maroto P, Algaba F et al (2007) Mixed transitional cell and small cell carcinoma of the bladder with metastases with neuroendocrine histology only. Arch Esp Urol 60(3):306–309PubMedCrossRef

28.

Dundr P, Pesl M, Povysil C et al (2003) Large endocrine carcinoma of the urinary bladder with lymphoepithelioma-like features. Pathol Res Pract 199(8):559–563PubMedCrossRef

Title: Serotonin used as prognostic marker of urological tumors
Authors: Nina Jungwirth
Lothar Haeberle
Karl Michael Schrott
Bernd Wullich
Frens Steffen Krause
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 5/2008
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-008-0285-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serotonin used as prognostic marker of urological tumors

Abstract

Introduction

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2008

Algorithms, nomograms and the detection of indolent prostate cancer

Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy

Three-dimensional ultrasound reconstruction of the pelvicaliceal system: an in-vitro study

Oncologic control provided by HIFU therapy as single treatment in men with clinically localized prostate cancer

Radical prostatectomy for low risk carcinoma of the prostate

Active surveillance for prostate cancer: trials and tribulations